Abstract
Introduction
Future time perspective (FTP) means the capacity to foresee, anticipate, and plan for future desired outcomes, and it contributes to persistent treatment for type 2 diabetes mellitus (T2DM). However, the components of FTP specific to T2DM patients have not been clarified. This study aimed to explore the components of FTP and to examine the associations between such components and persistent/impersistent diabetes treatment.
Methods
In this cross-sectional study, using qualitative and quantitative methods, 106 T2DM patients were enrolled by purposive sampling. The participants were interviewed in October and November 2018 by public health nurses in Koriyama City Public Health Center, Japan. In addition to the participants’ status of treatment engagement (persistent/impersistent), their responses regarding reasons for persistent/impersistent treatment were collected and then summarized into nine subthemes, which were then merged into two main themes according to the presence or absence of FTP with a sense of T2DM ownership for analysis.
Results
The main theme, “presence of FTP with a sense of T2DM ownership,” included subthemes such as “securing social independence,” “planning on living a long and healthy life,” “prioritizing avoiding being a burden on family and friends,” “valuing improvement of diabetes,” “avoiding tragic results,” “optimistically viewing treatment as a form of self-development,” and “improving mental health,” whereas the main theme, “absence of FTP with a sense of T2DM ownership,” included “lack of consciousness of disease” and “living a dissipated life.” The association between the presence of FTP with a sense of T2DM ownership and persistent treatment for T2DM was found using Fisher’s exact test (p < 0.001).
Conclusion
Health care professionals should support T2DM patients in having an FTP with a sense of T2DM ownership and purpose in life instead of treatment goals when such patients mention their dissipated life or lack of insight into the disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Takahashi, Noriko 2 ; Hashimoto, Katsue 2 ; Inoue, Mariko 3 ; Terada, Yukiko 3 ; Endo, Shota 1 ; Kakamu, Takeyasu 1 ; Tsukahara, Taro 2 ; Abe, Koichi 4 ; Fukushima, Tetsuhito 1 1 Fukushima Medical University, Department of Hygiene and Preventive Medicine, Fukushima, Japan (GRID:grid.411582.b) (ISNI:0000 0001 1017 9540)
2 Koriyama City Public Health Center, Koriyama, Japan (GRID:grid.411582.b)
3 Novo Nordisk Pharma Ltd., CMR Development Division, Tokyo, Japan (GRID:grid.411582.b)
4 Igarashi Clinic of Medicine and Surgery, Koriyama, Japan (GRID:grid.411582.b)





